Kaya Pai Panandiker

Equibles does not estimate personal net worth.

Get an email with a short summary when Lb Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.

Get LBRX alerts

About Kaya Pai Panandiker

Neumora Therapeutics, Inc. reported in an 8-K filed February 13, 2025 that Kaya Pai Panandiker resigned as Chief Commercial Officer, effective February 14, 2025. Lb Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lb Pharmaceuticals Inc includes Heather Turner (CEO and Board Member), Joseph M. Miller (CFO), Gad Soffer (COO) and 1 other.

“Kaya Pai Panandiker will depart the Company and no longer serve as Chief Commercial Officer.”

Neumora Therapeutics, Inc. Form 8-K, filed February 13, 2025 · Read the filing

Affiliation history

Lb Pharmaceuticals Inc (LBRX)
Proxy statement

Current
Start not stated–present

Last confirmed April 23, 2026

Company network

Lb Pharmaceuticals Inc

LBRX

Current role

Biotechnology · Healthcare

Leadership on record at Lb Pharmaceuticals Inc

Heather Turner CEO, Board Member
Joseph M. Miller CFO
Gad Soffer COO
Robert A. Lenz Board Member

Recent activity

Executive change Resigned: Chief Commercial Officer Neumora Therapeutics, Inc. (NMRA)
2025-02-14